$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

$lsta Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000032001718000038 Filed on May 10, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q4
Revenue	$0.00	$300.0K	$1.900M
YoY Change	-100.0%	-96.21%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.146M	$2.897M	$2.670M
YoY Change	-37.48%	7.04%	16.59%
% of Gross Profit
Research & Development	$2.123M	$2.262M	$4.650M
YoY Change	-50.37%	-39.29%	45.31%
% of Gross Profit
Depreciation & Amortization	$80.00K	$90.00K	$90.00K
YoY Change	-11.11%	-10.0%	-10.0%
% of Gross Profit
Operating Expenses	$4.269M	$5.159M	$7.320M
YoY Change	-44.63%	-19.8%	33.33%
Operating Profit	-$4.269M	-$5.159M
YoY Change	-44.63%	-19.8%
Interest Expense	$2.000K	$3.000K	-$10.00K
YoY Change	-99.02%	-98.11%	-94.44%
% of Operating Profit
Other Income/Expense, Net	$192.0K	$175.0K	$140.0K
YoY Change	-196.17%	-186.07%
Pretax Income	-$4.077M	-$4.984M	-$7.190M
YoY Change	-48.46%	-24.89%	26.81%
Income Tax	$0.00	$0.00	-$3.230M
% Of Pretax Income
Net Earnings	-$4.077M	-$4.984M	-$2.860M
YoY Change	-110.6%	-49.11%	-52.01%
Net Earnings / Revenue		-1661.33%	-150.53%
Basic Earnings Per Share
Diluted Earnings Per Share	-$425.4K	-$520.9K	-$302.3K
COMMON SHARES
Basic Shares Outstanding	9.570M shares	9.553M shares	9.471M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$50.32M	$48.58M	$55.08M
YoY Change	-15.24%	304.87%	678.33%
Cash & Equivalents	$22.73M	$21.60M	$29.16M
Short-Term Investments	$27.60M	$26.98M	$25.92M
Other Short-Term Assets	$1.200M	$5.800M	$6.300M
YoY Change	-88.79%	-13.43%	-63.79%
Inventory
Prepaid Expenses
Receivables		$144.3K	$234.5K
Other Receivables		$0.00
Total Short-Term Assets	$51.55M	$54.53M	$61.40M
YoY Change	-26.79%	148.61%	149.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$98.12K	$178.1K	$257.0K
YoY Change	-77.33%	-98.94%	-63.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$442.8K	$1.434M	$1.722M
YoY Change	-68.43%	118.78%	8.84%
Total Long-Term Assets	$540.9K	$2.187M	$1.979M
YoY Change	-70.53%	-91.78%	-93.14%
TOTAL ASSETS
Total Short-Term Assets	$51.55M	$54.53M	$61.40M
Total Long-Term Assets	$540.9K	$2.187M	$1.979M
Total Assets	$52.09M	$56.72M	$63.38M
YoY Change	-27.9%	16.87%	18.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$505.7K	$866.8K	$1.343M
YoY Change	-54.61%	-75.77%	-39.68%
Accrued Expenses	$5.299M	$6.998M	$7.812M
YoY Change	-57.3%	38.26%	193.75%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$100.0K	$0.00
YoY Change		-96.87%	-100.0%
Total Short-Term Liabilities	$5.828M	$7.957M	$9.314M
YoY Change	-59.95%	-65.72%	-56.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$2.798M	$3.444M	$3.873M
YoY Change	-23.06%	745.59%	893.44%
Total Long-Term Liabilities	$2.798M	$3.444M	$3.873M
YoY Change	-23.06%	63.34%	-86.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.828M	$7.957M	$9.314M
Total Long-Term Liabilities	$2.798M	$3.444M	$3.873M
Total Liabilities	$8.626M	$11.40M	$13.19M
YoY Change	-52.63%	-63.35%	-56.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$390.9M	-$386.8M	-$381.8M
YoY Change	4.11%	-6.61%	-5.68%
Common Stock	$9.735K	$9.575K	$9.000K
YoY Change	9.22%	6.95%	9.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$707.6K	$707.6K	$708.0K
YoY Change	0.0%	0.0%	0.05%
Treasury Stock Shares	11.08K shares	11.08K shares	11.08K shares
Shareholders Equity	$43.74M	$45.59M	$50.51M
YoY Change
Total Liabilities & Shareholders Equity	$52.09M	$56.72M	$63.38M
YoY Change	-27.9%	16.87%	18.43%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q4
OPERATING ACTIVITIES
Net Income	-$4.077M	-$4.984M	-$2.860M
YoY Change	-110.6%	-49.11%	-52.01%
Depreciation, Depletion And Amortization	$80.00K	$90.00K	$90.00K
YoY Change	-11.11%	-10.0%	-10.0%
Cash From Operating Activities	-$5.880M	-$6.299M	-$3.970M
YoY Change	1100.0%	-37.56%	17.46%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$9.000K	-$20.00K
YoY Change	-100.0%	-87.08%	-33.33%
Acquisitions
YoY Change
Other Investing Activities	$1.840M	-$1.180M	$18.26M
YoY Change	-93.19%	1080.0%	-3752.0%
Cash From Investing Activities	$1.840M	-$1.189M	$18.23M
YoY Change	-93.19%	594.2%	-3539.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	160.0K	-$72.00K	-180.0K
YoY Change	-101.53%	-100.95%
NET CHANGE
Cash From Operating Activities	-5.880M	-$6.299M	-3.970M
Cash From Investing Activities	1.840M	-$1.189M	18.23M
Cash From Financing Activities	160.0K	-$72.00K	-180.0K
Net Change In Cash	-3.880M	-$7.560M	14.08M
YoY Change	-124.17%	179.23%	-460.1%
FREE CASH FLOW
Cash From Operating Activities	-$5.880M	-$6.299M	-$3.970M
Capital Expenditures	$0.00	$9.000K	-$20.00K
Free Cash Flow	-$5.880M	-$6.308M	-$3.950M
YoY Change	1178.26%	-37.9%	17.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	clbs	Aggregate Intrinsic Value Warrants Outstanding AggregateIntrinsicValueWarrantsOutstanding	0	USD
CY2018Q1	clbs	Aggregate Intrinsic Value Warrants Outstanding AggregateIntrinsicValueWarrantsOutstanding	0	USD
CY2018Q1	clbs	Aggregate Intrinsic Value Warrantsvested AggregateIntrinsicValueWarrantsvested	0	USD
CY2018Q1	clbs	Aggregate Intrinsic Value Warrantsvestedandexpectedtovest AggregateIntrinsicValueWarrantsvestedandexpectedtovest	0	USD
CY2017Q1	clbs	Changein Ownershipin Subsidiary ChangeinOwnershipinSubsidiary	0	USD
CY2018Q1	clbs	Changein Ownershipin Subsidiary ChangeinOwnershipinSubsidiary	0	USD
CY2017Q4	clbs	Common Stock Warrants Shares CommonStockWarrantsShares	209818	shares
CY2018Q1	clbs	Common Stock Warrants Shares CommonStockWarrantsShares	51154	shares
CY2017Q1	clbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-560032	USD
CY2018Q1	clbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-1717871	USD
CY2016Q4	clbs	Interim Efficacy Analysis Followup Milestone Period InterimEfficacyAnalysisFollowupMilestonePeriod	P6M
CY2017Q4	clbs	Market Capitalization Used In Net Operating Loss Analysis MarketCapitalizationUsedInNetOperatingLossAnalysis	124500000	USD
CY2017Q1	clbs	Net Operating Loss Analysis Annual Limitation NetOperatingLossAnalysisAnnualLimitation	3000000	USD
CY2018Q1	clbs	Number Of Patients Enrolled NumberOfPatientsEnrolled	110	patient
CY2017Q4	clbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
CY2018Q1	clbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
CY2018Q1	clbs	Sharesvestedandexpectedtovest Sharesvestedandexpectedtovest	51154	shares
CY2018Q1	clbs	Warrants Canceled WarrantsCanceled	0	shares
CY2018Q1	clbs	Warrants Exercised WarrantsExercised	0	shares
CY2018Q1	clbs	Warrants Expired WarrantsExpired	158664	shares
CY2018Q1	clbs	Warrants Granted WarrantsGranted	0	shares
CY2018Q1	clbs	Warrants Vested WarrantsVested	51154	shares
CY2018Q1	clbs	Weighted Average Exercise Price Warrants Canceled WeightedAverageExercisePriceWarrantsCanceled	0.00
CY2018Q1	clbs	Weighted Average Exercise Price Warrants Exercisable WeightedAverageExercisePriceWarrantsExercisable	62.70
CY2018Q1	clbs	Weighted Average Exercise Price Warrants Exercised WeightedAverageExercisePriceWarrantsExercised	0.00
CY2018Q1	clbs	Weighted Average Exercise Price Warrants Expired WeightedAverageExercisePriceWarrantsExpired	50.20
CY2018Q1	clbs	Weighted Average Exercise Price Warrants Granted WeightedAverageExercisePriceWarrantsGranted	0.00
CY2016Q4	clbs	Number Of Patients Enrolled NumberOfPatientsEnrolled	19	patient
CY2016Q4	clbs	Interim Efficacy Analysis Percentage Threshold InterimEfficacyAnalysisPercentageThreshold	0.50
CY2018Q1	clbs	Weighted Average Remaining Contractual Termwarrantoutstanding WeightedAverageRemainingContractualTermwarrantoutstanding	P3Y1M6D
CY2017Q4	clbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	53.20
CY2018Q1	clbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	62.70
CY2018Q1	clbs	Weighted Average Exercise Price Warrantsvestedexpectedtovest WeightedAverageExercisePriceWarrantsvestedexpectedtovest	62.70
CY2018Q1	clbs	Weighted Average Remaining Contractual Term Warrants Vestedand Expectto Vest WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest	P3Y1M6D
CY2017	clbs	Weighted Average Remaining Contractual Termwarrantoutstanding WeightedAverageRemainingContractualTermwarrantoutstanding	P0Y11M12D
CY2018Q1	clbs	Weighted Average Remaining Contractual Termwarrantsvested WeightedAverageRemainingContractualTermwarrantsvested	P3Y1M6D
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000320017
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9569853	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	Caladrius Biosciences, Inc.
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1343089	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	866840	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	234461	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	144256	USD
CY2017Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2018Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-82221	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7810948	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6998396	USD
CY2017Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	7811000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	6998000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	287000	USD
CY2018Q1	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	161000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-27978	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-58724	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	433044209	USD
CY2018Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	433137593	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	533000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	146000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2018Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2017Q4	us-gaap	Assets Assets	63375682	USD
CY2018Q1	us-gaap	Assets Assets	56716514	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	61109645	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	54529273	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	42326000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	28000	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	55000	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	51913000	USD
CY2018Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	42326000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis	42326000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue	42271000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis	0	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	0	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	51885000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	42271000	USD
CY2017Q4	us-gaap	Cash Cash	25968000	USD
CY2018Q1	us-gaap	Cash Cash	15287000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29163200	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21600899	USD
CY2017Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	51885000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	42271000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7076651	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8915507	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34167989	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26608430	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	7628357	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	3082099	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	0	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	0	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11997606	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26608430	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2707402	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-7559559	USD
CY2017Q1	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-116545	USD
CY2018Q1	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0	USD
CY2017Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-101626	USD
CY2018Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
CY2017Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-5494638	USD
CY2018Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9483911	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9574685	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9483911	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9574685	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	9484	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	9575	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9359827	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5013325	USD
CY2018Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1	shares
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-433497	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1862	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-9793324	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-5015187	USD
CY2017Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1	shares
CY2017Q4	us-gaap	Customer Advances Current CustomerAdvancesCurrent	2446000	USD
CY2018Q1	us-gaap	Customer Advances Current CustomerAdvancesCurrent	2583000	USD
CY2017Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	575055	USD
CY2018Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	575055	USD
CY2017Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	98924	USD
CY2018Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	87324	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.12
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
CY2017Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	1389000	USD
CY2018Q1	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	666000	USD
CY2016Q1	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.199
CY2018Q1	us-gaap	Grants Receivable GrantsReceivable	8600000	USD
CY2017Q1	us-gaap	Grants Receivable GrantsReceivable	12200000	USD
CY2017Q2	us-gaap	Grants Receivable Current GrantsReceivableCurrent	5700000	USD
CY2017Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	47301	USD
CY2018Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-6571183	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-4982579	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-64666	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-1862	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6635849	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4984441	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-6635849	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-4984441	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.78
CY2018Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.52
CY2017Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-3157475	USD
CY2018Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	USD
CY2017Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	-368831	USD
CY2018Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2017Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-2788644	USD
CY2018Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2017Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.33
CY2018Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.00
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2018Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-10510	USD
CY2017Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	400000	USD
CY2018Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	300000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	13185896	USD
CY2018Q1	us-gaap	Liabilities Liabilities	11400893	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63375682	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	56716514	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9313217	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7957284	USD
CY2017Q4	us-gaap	Marketable Securities MarketableSecurities	25917000	USD
CY2017Q4	us-gaap	Marketable Securities MarketableSecurities	25916681	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-90204	USD
CY2017Q1	us-gaap	Increase Decrease In Due From Affiliates Current IncreaseDecreaseInDueFromAffiliatesCurrent	-1943774	USD
CY2018Q1	us-gaap	Increase Decrease In Due From Affiliates Current IncreaseDecreaseInDueFromAffiliatesCurrent	0	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-20141	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-86263	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2447	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	158928	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	3295	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	130204	USD
CY2018Q1	us-gaap	Interest Paid InterestPaid	3295	USD
CY2017Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	395698	USD
CY2018Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	146533	USD
CY2018Q1	us-gaap	Marketable Securities MarketableSecurities	26984000	USD
CY2018Q1	us-gaap	Marketable Securities MarketableSecurities	26983626	USD
CY2017Q4	us-gaap	Minority Interest MinorityInterest	-318283	USD
CY2018Q1	us-gaap	Minority Interest MinorityInterest	-272598	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7551782	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-72641	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	7668327	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-72641	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-171276	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1188441	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-69650	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1188441	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10087908	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6298477	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4593270	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6298477	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9359827	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4982579	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-203323	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	174243	USD
CY2017Q4	us-gaap	Notes Payable NotesPayable	200000	USD
CY2018Q1	us-gaap	Notes Payable NotesPayable	100000	USD
CY2017Q4	us-gaap	Notes Payable Current NotesPayableCurrent	159180	USD
CY2018Q1	us-gaap	Notes Payable Current NotesPayableCurrent	92048	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	6432526	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	5158684	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6432526	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5158684	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3004000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	129000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	474000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	827000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	905000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	669000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	1456000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	1355000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1434077	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1434077	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-30746	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-30746	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-30746	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3872679	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3443609	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-44395	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	177538	USD
CY2017Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	23647	USD
CY2018Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	45169	USD
CY2017Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2018Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	24143913	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	69650	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8528	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	790514	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	792961	USD
CY2017Q1	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	5000000	USD
CY2018Q1	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	0	USD
CY2017Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3241460	USD
CY2018Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2017Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	400998	USD
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	100	USD
CY2018Q1	us-gaap	Preferred Stock Value PreferredStockValue	100	USD
CY2018Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	22964000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	39659	USD
CY2017Q1	us-gaap	Profit Loss ProfitLoss	-9793324	USD
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-4984441	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	256905	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	178109	USD
CY2017Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	756966	USD
CY2018Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2017Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	193518	USD
CY2018Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	67131	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3726132	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2262240	USD
CY2017Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	5004789	USD
CY2018Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	5007531	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-381810109	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-386792688	USD
CY2017Q4	us-gaap	Retention Payable RetentionPayable	2233000	USD
CY2018Q1	us-gaap	Retention Payable RetentionPayable	2233000	USD
CY2017Q4	us-gaap	Revenue From Grants RevenueFromGrants	1900000	USD
CY2018Q1	us-gaap	Revenue From Grants RevenueFromGrants	300000	USD
CY2018Q1	us-gaap	Revenue From Grants RevenueFromGrants	7900000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2706394	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2896444	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	1900000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	300000	USD
CY2016Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.72
CY2017Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	132726	shares
CY2018Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	127688	shares
CY2017Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3241460	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	470000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	351000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	509550	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	101363	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	39659	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	50508069	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	45588219	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4066480	USD
CY2017Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1975834	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50189786	USD
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	45315621	USD
CY2017Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	11080	shares
CY2018Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	11080	shares
CY2017Q4	us-gaap	Treasury Stock Value TreasuryStockValue	707637	USD
CY2018Q1	us-gaap	Treasury Stock Value TreasuryStockValue	707637	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8386903	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9557347	shares
CY2018Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Risks</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to credit risk from our portfolio of cash, cash equivalents, restricted cash, and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</font></div></div>

Files In Submission

Name	View Source	Status
0000320017-18-000038-index-headers.html	Edgar Link	pending
0000320017-18-000038-index.html	Edgar Link	pending
0000320017-18-000038.txt	Edgar Link	pending
0000320017-18-000038-xbrl.zip	Edgar Link	pending
clbs-10qx20180331.htm	Edgar Link	pending
clbs-20180331.xml	Edgar Link	completed
clbs-20180331.xsd	Edgar Link	pending
clbs-20180331_cal.xml	Edgar Link	unprocessable
clbs-20180331_def.xml	Edgar Link	unprocessable
clbs-20180331_lab.xml	Edgar Link	unprocessable
clbs-20180331_pre.xml	Edgar Link	unprocessable
clbs-ex311_20180331xq1.htm	Edgar Link	pending
clbs-ex312_20180331xq1.htm	Edgar Link	pending
clbs-ex321_20180331xq1.htm	Edgar Link	pending
clbs-ex322_20180331xq1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

2018 Q2 Form 10-Q Financial Statement

#000032001718000038 Filed on May 10, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA LISATA THERAPEUTICS, INC. Stock $lsta

2018 Q2 Form 10-Q Financial Statement

#000032001718000038 Filed on May 10, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta